Introduction: Hypertrophic cardiomyopathy (HCM) belongs to the very heterogeneous group of cardiomyopathies. This study aimed to study myocardial perfusion abnormalities on scintigraphy and assess the risk of sudden d...Introduction: Hypertrophic cardiomyopathy (HCM) belongs to the very heterogeneous group of cardiomyopathies. This study aimed to study myocardial perfusion abnormalities on scintigraphy and assess the risk of sudden death from ventricular arrhythmia in hereditary sarcomeric HCM. Patients and Methods: This is a retrospective and prospective descriptive study over 18 months (January 01, 2021, to July 31, 2022) on the records of patients over 18 with the diagnosis of hypertrophic sarcomeric cardiomyopathy with or without ventricular rhythm disorders and who have undergone myocardial scintigraphy. Results: Three patients were included. The average age of our patients was 66 years old. Dyspnea is the primary symptomatology found in our patients. One patient presented with syncope and unsustained ventricular tachycardia. His risk score for sudden death from ESC at five years is estimated at 6.45%, and the patient received an ICD in primary prevention. The average sudden death risk score of our patients was 3.78%. The mean LV wall thickness was 20 mm. The mean maximum left intraventricular gradient was 39 mmHg. Myocardial fibrosis was present in all our patients. Myocardial scintigraphy was normal in all cases. Conclusion: Hypertrophic cardiomyopathy is a very heterogeneous group of cardiomyopathies. The rhythmic risk is multifactorial and constitutes a significant prognostic factor.展开更多
目的观察具备起搏模式策略和AV间期延长的策略功能的起搏器(Adapta)的远期临床效果。方法 39例患者随机分组,置入具有自动化功能的Adapta起搏器(实验组,n=20)和其它类型双腔起搏器(对照组,n=19)。并分别在置入前及置入后1,2年进行随访...目的观察具备起搏模式策略和AV间期延长的策略功能的起搏器(Adapta)的远期临床效果。方法 39例患者随机分组,置入具有自动化功能的Adapta起搏器(实验组,n=20)和其它类型双腔起搏器(对照组,n=19)。并分别在置入前及置入后1,2年进行随访。随访中观察两组的右室起搏比例、心功能(纽约心功能分级、血脑钠肽)、左房内径(LAD)、左室舒张末内径(LVEDD)、左室射血分数、持续性心房颤动发生率及生活质量等的变化。结果置入双腔起搏器术后1年及2年,与对照组比较,实验组心室起搏比例均明显降低(38.21%±46.01%vs 92.52%±2.70%;36.22%±73.09%vs 91.78%±7.63%,P均<0.05)。置入术后2年,对照组与实验组及与自身术前比较,LAD,LVEDD增大(LAD:43.11±7.08 mm vs 39.01±3.72 mm,40.02±4.70 mm;LVEDD:53.60±6.91 mm vs 47.71±4.79 mm,46.57±3.99 mm,P均<0.05)。其他指标两组无明显差异。结论起搏器自动化功能可以有效降低心室起搏比例、保护心功能。展开更多
文摘Introduction: Hypertrophic cardiomyopathy (HCM) belongs to the very heterogeneous group of cardiomyopathies. This study aimed to study myocardial perfusion abnormalities on scintigraphy and assess the risk of sudden death from ventricular arrhythmia in hereditary sarcomeric HCM. Patients and Methods: This is a retrospective and prospective descriptive study over 18 months (January 01, 2021, to July 31, 2022) on the records of patients over 18 with the diagnosis of hypertrophic sarcomeric cardiomyopathy with or without ventricular rhythm disorders and who have undergone myocardial scintigraphy. Results: Three patients were included. The average age of our patients was 66 years old. Dyspnea is the primary symptomatology found in our patients. One patient presented with syncope and unsustained ventricular tachycardia. His risk score for sudden death from ESC at five years is estimated at 6.45%, and the patient received an ICD in primary prevention. The average sudden death risk score of our patients was 3.78%. The mean LV wall thickness was 20 mm. The mean maximum left intraventricular gradient was 39 mmHg. Myocardial fibrosis was present in all our patients. Myocardial scintigraphy was normal in all cases. Conclusion: Hypertrophic cardiomyopathy is a very heterogeneous group of cardiomyopathies. The rhythmic risk is multifactorial and constitutes a significant prognostic factor.
文摘目的观察具备起搏模式策略和AV间期延长的策略功能的起搏器(Adapta)的远期临床效果。方法 39例患者随机分组,置入具有自动化功能的Adapta起搏器(实验组,n=20)和其它类型双腔起搏器(对照组,n=19)。并分别在置入前及置入后1,2年进行随访。随访中观察两组的右室起搏比例、心功能(纽约心功能分级、血脑钠肽)、左房内径(LAD)、左室舒张末内径(LVEDD)、左室射血分数、持续性心房颤动发生率及生活质量等的变化。结果置入双腔起搏器术后1年及2年,与对照组比较,实验组心室起搏比例均明显降低(38.21%±46.01%vs 92.52%±2.70%;36.22%±73.09%vs 91.78%±7.63%,P均<0.05)。置入术后2年,对照组与实验组及与自身术前比较,LAD,LVEDD增大(LAD:43.11±7.08 mm vs 39.01±3.72 mm,40.02±4.70 mm;LVEDD:53.60±6.91 mm vs 47.71±4.79 mm,46.57±3.99 mm,P均<0.05)。其他指标两组无明显差异。结论起搏器自动化功能可以有效降低心室起搏比例、保护心功能。
